Carbamazepine drug reaction involving high fevers during the COVID-19 era

Reuben Heyman-Kantor*, Matthew Perez, Arti Phatak, Danielle L. Anderson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Carbamazepine has demonstrated anticonvulsant properties and is used for a variety of indications in psychiatry and neurology. Total daily doses typically range from 200 to 1200 mg/d, generally divided into 2 doses. Carbamazepine has a broad side-effect profile but is not typically thought to produce high fevers in the absence of a hypersensitivity syndrome. This is a case of a probable adverse drug reaction to carbamazepine consisting of fever without severe major organ involvement. In this instance, a patient in a manic episode with psychotic features was briefly transferred to a COVID-19 unit to rule out coronavirus infection before the fever resolved.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalMental Health Clinician
Volume11
Issue number5
DOIs
StatePublished - Sep 2021

Keywords

  • Adverse drug reaction
  • Bipolar disorder
  • COVID-19
  • Carbamazepine
  • Case report
  • Coronavirus

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology

Fingerprint

Dive into the research topics of 'Carbamazepine drug reaction involving high fevers during the COVID-19 era'. Together they form a unique fingerprint.

Cite this